References 1. Dietary Supplement Health and Education Act of 1994. http://thomas.loc.gov/ cgi-bin/query/d?c103:6:./temp~ c103705qih:e13550 (accessed 2000 Sep 20). 2. Gugliotta G. Health concerns grow over herbal aids. http://washingtonpost.com/ wp-dn/articles/a32685-2000mar17.html (accessed 2000 Sep 20). 3. American Society of Health-System Pharmacists. Snapshot of medication use in the US. www.ashp.org/public/ public_relations/snapshot.pdf (accessed 2001 Feb 3). 4. Food and Drug Administration. Regulations on statements made for dietary supplements concerning the effect of the product on the structure or function of the body; final rule. Fed Reg. 2000; 65: 1000-5. 5. Jellin JM, Gregory P, Batz F et al., eds. Pharmacist's letter/prescriber's letter natural medicines comprehensive database. www.naturaldatabase.com (accessed 2001 Feb 3). 6. Durr D, Stieger B, Kullak-Ublick GA et al. St John's wort induces intestinal Pglycoprotein/ MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther. 2000; 68:598-604. 7. Rothkopf M, Vogel G, Lang W et al. Animal experiments on the question of the renal toleration of the horse chestnut saponin aescin. Arzneimittelforschung. 1977; 27:598-605. 8. Ruschitzka F, Meier PJ, Turina M et al. Acute heart transplant rejection due to Saint John's wort. Lancet. 2000; 355: 548-9. 9. Piscitelli SC, Burstein AH, Chaitt D et al. Indinavir concentrations and St John's wort. Lancet. 2000; 355:547-8. 10. Roby CA, Anderson GD, Kantor E et al. St John's wort: effect on CYP3A4 activity. Clin Pharmacol Ther. 2000; 67:451-7. 11. Food and Drug Administration. Risk of drug interactions with St. John's wort and indinavir and other drugs. www.fda.gov/ cder/drug/advisory/stjwort.htm (accessed 2000 Oct 31). 12. Yue QY, Bergquist C, Gerden B. Safety of St John's wort (Hypericum perforatum). Lancet. 2000; 355:576-7. 13. Yu DK. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J Clin Pharmacol. 1999; 39: 1203-11. 14. Monostory K, Vereczkey L, Levai F et al. Ipriflavone as an inhibitor of human cytochrome P450 enzymes. Br J Pharmacol. 1998; 123:605-10. 15. Food and Drug Administration. Office of Special Nutritionals Adverse Event Monitoring System. http://vm.cfsan. fda.gov/cgi-bin/aems.cgi?query= ephedra+&stype=exact (accessed 2000 Nov 15). 16. Theoharides TC. Sudden death of a healthy college student related to ephedrine toxicity from a ma huangcontaining drink. J Clin Psychopharmacol. 1997; 17:437-9. 17. Budzinski JW, Foster BC, Vandenhoek S et al. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine. 2000; 7:273-82. 18. Georgetown University Medical Center. Cytochrome P-450 drug interaction table. www.georgetown.edu/departments/ pharmacology/davetab.html (accessed 2001 Feb 3). 19. Hansten PD, Horn JR, eds. Drug analysis and management. St. Louis, MO: Facts and Comparisons; 1999. 20. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998; 18:84-112. 21. Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet. 1994; 344:1372-3. 22. Landbo C, Almdal TP. [Interaction between warfarin and coenzyme Q10]. Ugeskr Laeger. 1998; 160:3226-7. In Danish. 23. Combs AB, Porter TH, Folkers K. Anticoagulant activity of a naphthoquinone analog of vitamin K and an inhibitor of coenzyme Q10-enzyme systems. Res Commun Chem Pathol Pharmacol. 1976; 13:109-14. 24. Page RL II, Lawrence JD. Potentiation of warfarin by dong quai. Pharmacotherapy. 1999; 19:870-6. 25. Mei QB, Tao JY, Cui B. Advances in the pharmacological studies of radix Angelica sinensis (Oliv) Diels (Chinese danggui). Chin Med J (Engl). 1991; 104:776-81. 26. Foster S, Tyler VE. Tyler's honest herbal: a sensible guide to the use of herbs and related remedies. 4th ed. New York: Hawthorn Herbal; 1999. 27. Gurley BJ, Gardner SF, Hubbard MA. Content versus label claims in ephedracontaining dietary supplements. Am J Health-Syst Pharm. 2000; 57:963-9. 28. McEvoy GK, ed. AHFS drug information. Bethesda, MD: American Society of Health-System Pharmacists; 2000. 29. Dawson JK, Earnshaw SM, Graham CS. Dangerous monoamine oxidase inhibitor interactions are still occurring in the 1990s. J Accid Emerg Med. 1995; 12:49-51. 30. Piscitelli SC, Burstein AH, Welden N et al. Garlic supplements decrease saquinavir plasma concentrations. Paper presented at Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, IL; 2001. 31. Rose KD, Croissant PD, Parliament CF et al. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report. Neurosurgery. 1990; 26:880-2. 32. Legnani C, Frascaro M, Guazzaloca G et al. Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects. Arzneimittelforschung. 1993; 43:119-22. 33. Burnham BE. Garlic as a possible risk for postoperative bleeding. Plast Reconstr Surg. 1995; 95:213. Letter. 34. German K, Kumar U, Blackford HN. Garlic and the risk of TURP bleeding. Br J Urol. 1995; 76:518. 35. Srivas KC. Effects of aqueous extracts of onion, garlic and ginger on platelet aggregation and metabolism of arachidonic acid in the blood vascular system: in vitro study. Prostaglandins Leukot Med. 1984; 13:227-35. 36. Bordia A, Verma SK, Srivastava KC. Effect of ginger (Zingiber officinale Rosc.) and fenugreek (Trigonella foenumgraecum L.) on blood lipids, blood sugar and platelet aggregation in patients with coronary artery disease. 37. Prostaglandins Leukot Essent Fatty Acids. 1997; 56:379- 84. 38. Janssen PL, Meyboom S, van Staveren WA et al. Consumption of ginger (Zingiber officinale roscoe) does not affect ex vivo platelet thromboxane production in humans. Eur J Clin Nutr. 1996; 50:772-4. 39. Lumb AB. Effect of dried ginger on human platelet function. Thromb Haemost. 1994; 71:110-1. 40. Galluzzi S, Zanetti O, Binetti G et al. Coma in a patient with Alzheimer's disease taking low dose trazodone and Gingko biloba. J Neurol Neurosurg Psychiatry. 2000; 68:679-80. 41. Sasaki K, Hatta S, Haga M et al. Effects of bilobalide on gamma-aminobutyric acid levels and glutamic acid decarboxylase in mouse brain. Eur J Pharmacol. 1999; 367:165-73. 42. Rotzinger S, Fang J, Baker GB. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos. 1998; 26:572-5. 43. Diamond BJ, Shiflett SC, Feiwel N et al. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil. 2000; 81:668-78. 44. Chung KF, Dent G, McCusker M et al. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. Lancet. 1987; 1:248-51. 45. Matthews MK Jr. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology. 1998; 50:1933-4. 46. Mohutsky MA, Elmer GW. Inhibition of cytochrome P450 in vitro by the herbal product Ginkgo biloba. Paper presented at the 41st Annual Meeting of the American Society of Pharmacognosy. Seattle, WA; 2000 Jul. 47. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology. 1996; 46:1775-6. 48. Gilbert GJ. Ginkgo biloba. Neurology. 1997; 48:1137. Letter. 49. Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet. 1998; 352:36. Letter. 50. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med. 1997; 336:1108. Letter. 51. Benjamin J, Muir T, Briggs K et al. A case of cerebral haemorrhage -- can Ginkgo biloba be implicated? Postgrad Med J. 2001; 77:112-3. 52. Sotaniemi EA, Haapakoski E, Rautio A. Ginseng therapy in non-insulindependent diabetic patients. Diabetes Care. 1995; 18:1373-5. 53. Vuksan V, Sievenpiper JL, Koo VY et al. American ginseng (Panax quinquefolius L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. Arch Intern Med. 2000; 160:1009-13. 54. Vuksan V, Stavro MP, Sievenpiper JL et al. Similar postprandial glycemic reductions with escalation of dose and administration time of American ginseng in type 2 diabetes. Diabetes Care. 2000; 23:1221-6. 55. Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health-Syst Pharm. 1997; 54:692-3. 56. Zhu M, Chan KW, Ng LS et al. Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. J Pharm Pharmacol. 1999; 51:175-80. 57. Monauni T, Zenti MG, Cretti A et al. Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes. 2000; 49:926-35. 58. Nelson BA, Robinson KA, Buse MG. High glucose and glucosamine induce insulin resistance via different mechanisms in 3T3-L1 adipocytes. Diabetes. 2000; 49: 981-91. 59. Takahashi J, Kawakatsu K, Wakayama T et al. Elevation of serum theophylline levels by ipriflavone in a patient with chronic obstructive pulmonary disease. Eur J Clin Pharmacol. 1992; 43:207-8. 60. Evans AM. Influence of dietary components on the gastrointestinal metabolism and transport of drugs. Ther Drug Monit. 2000; 22:131-6. 61. Hartter S, Grozinger M, Weigmann H et al. Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther. 2000; 67:1-6. 62. Von Bahr C, Ursing C, Yasui N et al. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects -- an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. Eur J Clin Pharmacol. 2000; 56:123-7. 63. Lusardi P, Piazza E, Fogari R. Cardiovascular effects of melatonin in hypertensive patients well controlled by nifedipine: a 24-hour study. Br J Clin Pharmacol. 2000; 49:423-7. 64. Carson SW, Hill-Zabala CE, Roberts SH et al. Inhibitory effect of methanolic solution of St. John's wort (Hypericum perforatum) on cytochrome P450 3A4 activity in human liver microsomes. Clin Pharmacol Ther. 2000; 67:99. Abstract. 65. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther. 2000; 294:88-95. 66. Breidenbach T, Kliem V, Burg M et al. Profound drop of cyclosporin A whole blood trough levels caused by St. John's wort (Hypericum perforatum). Transplantation. 2000; 69:2229-30. 67. Markowitz JS, DeVane CL, Boulton DW et al. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci. 2000; 66:PL133-9. 68. Breidenbach T, Hoffmann MW, Becker T et al. Drug interaction of St John's wort with cyclosporin. Lancet. 2000; 355:1912. Letter. 69. Moore LB, Goodwin B, Jones SA et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A. 2000; 97:7500-2. 70. Wentworth JM, Agostini M, Love J et al. St John's wort, a herbal antidepressant, ac-tivates the steroid X receptor. J Endocrin- ol. 2000; 166:R11-6. 71. Roots I, Johne A, Schmider J et al. Interaction of a herbal extract from St. John's wort with amitriptyline and its metabolites. Clin Pharmacol Ther. 2000; 67:159. Abstract. 72. Barone GW, Gurley BJ, Ketel BL et al. Drug interaction between St. John's wort and cyclosporine. Ann Pharmacother. 2000; 34:1013-6. 73. Abul-Ezz SR, Barone GW, Gurley BJ et al. Effects of herbal supplements on cyclosporine blood levels and associated acute rejection. Paper presented at American Society of Nephrology Annual Meeting. Toronto, Canada; 2000 Oct. 74. Burstein AH, Horton RL, Dunn T et al. Lack of effect of St John's wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther. 2000; 68:605-12. 75. Gordon JB. SSRIs and St. John's wort: possible toxicity? Am Fam Physician. 1998; 57:950,953. Letter. 76. Schneck C. St. John's wort and hypomania. J Clin Psychiatry. 1998; 59:689. Letter. 77. Cheng TO. St John's wort interaction with digoxin. Arch Intern Med. 2000; 160:2548. Letter. 78. Johne A, Brockmoller J, Bauer S et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther. 1999; 66:338-45. 79. Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med. 1996; 125:940-1.78. 80. McRae S. Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng. Can Med Assoc J. 1996; 155: 293-5. 81. Awang DV. Siberian ginseng toxicity may be case of mistaken identity. Can Med Assoc J. 1996; 155:1237. Letter. 82. Federal Trade Commission. Dietary supplements: an advertising guide for industry, 2001. www.ftc.gov/bcp/conline/ pubs/buspubs/dietsupp.htm (accessed 2001 Feb 3). Acknowledgements The contributions and assistance of Forrest Batz, Pharm.D., and Joe Pepping, Pharm.D., are acknowledged. Gayle Nicholas Scott, Pharm.D., FASCP, BCPS, CGP, is a freelance medical writer and Assistant Professor, Department of Physiological Sciences, Eastern Virginia Medical School, Norfolk. Gary W. Elmer, PH.D., is Professor, Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle. Address correspondence to Dr. Scott at Medical Communications and Consulting, 609 Fordsmere Road, Chesapeake, VA 23322-2127 (gscottphar@aol.com). Remember we are NOT Doctors and have NO medical training. This site is like an Encylopedia - there are many pages, many links on many topics. Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.